Kanghong Pharmaceutical announced that recently, its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and KHN921 injection was approved to conduct clinical trials to treat hypertrophic cardiomyopathy caused by MYBPC3 mutations. This product is an AAV gene therapy product independently developed by Hongji Biotech. In April 2026, it was approved by the US Drug Administration to conduct clinical trials in the US. Investors are reminded to pay attention to risks due to uncertain results and timing such as drug development.
Zhitongcaijing · 1d ago
Share
Listen to the news
Kanghong Pharmaceutical announced that recently, its subsidiary Chengdu Hongji Biotechnology Co., Ltd. received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, and KHN921 injection was approved to conduct clinical trials to treat hypertrophic cardiomyopathy caused by MYBPC3 mutations. This product is an AAV gene therapy product independently developed by Hongji Biotech. In April 2026, it was approved by the US Drug Administration to conduct clinical trials in the US. Investors are reminded to pay attention to risks due to uncertain results and timing such as drug development.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending